Hologic, Inc. (NASDAQ:HOLX) Shares Sold by ING Groep NV

ING Groep NV cut its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 71.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,121 shares of the medical equipment provider's stock after selling 82,283 shares during the quarter. ING Groep NV's holdings in Hologic were worth $2,698,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Prentiss Smith & Co. Inc. increased its stake in Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider's stock worth $3,967,000 after acquiring an additional 130 shares during the last quarter. Covestor Ltd grew its stake in shares of Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider's stock valued at $56,000 after buying an additional 133 shares in the last quarter. Massmutual Trust Co. FSB ADV grew its stake in shares of Hologic by 20.3% in the second quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider's stock valued at $62,000 after buying an additional 140 shares in the last quarter. Wedmont Private Capital grew its stake in shares of Hologic by 3.7% in the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider's stock valued at $361,000 after buying an additional 162 shares in the last quarter. Finally, Sequoia Financial Advisors LLC grew its stake in shares of Hologic by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider's stock valued at $536,000 after buying an additional 165 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on HOLX. UBS Group increased their target price on Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Leerink Partners reduced their price target on Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Royal Bank of Canada increased their price target on Hologic from $86.00 to $89.00 and gave the company a "sector perform" rating in a report on Tuesday, November 5th. StockNews.com raised Hologic from a "hold" rating to a "buy" rating in a report on Thursday. Finally, JPMorgan Chase & Co. increased their price target on Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $89.91.

Hologic Stock Performance

NASDAQ:HOLX traded up $1.06 during trading hours on Friday, reaching $78.60. 1,834,908 shares of the stock were exchanged, compared to its average volume of 1,625,425. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The firm has a 50 day simple moving average of $80.71 and a 200-day simple moving average of $78.25. Hologic, Inc. has a 52 week low of $67.59 and a 52 week high of $84.67. The stock has a market capitalization of $18.26 billion, a P/E ratio of 23.60, a P/E/G ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business's revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the business posted $0.89 EPS. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.